Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine

Completed

Conditions studied: Migraine Disorders

In brief

This protocol describes the analysis of the Adelphi Real World (ARW) Migraine Disease Specific Programme(TM) 2022, a cross-sectional study which used both physician and patient surveys to assess the perception of the acute treatment for migraine attacks.

Key facts

Study ID

NCT06412965

Run by

Pfizer

People needed

528

Starts

2024-01-02

Expected to finish

2024-01-03

Last updated by the study team

2025-01-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who have episodic and/or chronic migraine
• Patients age > 18
• Currently prescribed rimegepant OR triptans for the acute treatment of migraine

You may not qualify if…

• currently prescribed rimegepant for prevention of migraine or for both the acute treatment \& prevention of migraine
• Rimegepant group: currently prescribed an acute treatment for migraine and other than rimegepant
• Triptan Group: currently prescribed an acute treatment for migraine other than triptans

Where it is running

• Pfizer — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.